We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Inability to Quickly Nix Unpromising Drug Projects Hurts R&D, Survey Finds
Inability to Quickly Nix Unpromising Drug Projects Hurts R&D, Survey Finds
February 14, 2005
While the number of new molecular entities (NMEs) approved by the FDA has increased in recent years, drug researchers believe it’s getting harder to develop drugs and get approvals for their products, according to a new survey.